Compare IMXI & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMXI | PHAR |
|---|---|---|
| Founded | 1994 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 469.3M | 1.2B |
| IPO Year | 2016 | 2020 |
| Metric | IMXI | PHAR |
|---|---|---|
| Price | $15.24 | $13.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $15.00 | ★ $38.33 |
| AVG Volume (30 Days) | ★ 754.6K | 12.1K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $319,601,000.00 | N/A |
| Revenue This Year | $0.83 | $10.04 |
| Revenue Next Year | $1.49 | $2.51 |
| P/E Ratio | ★ $762.75 | $3,041.22 |
| Revenue Growth | ★ 16.68 | N/A |
| 52 Week Low | $8.58 | $9.54 |
| 52 Week High | $15.95 | $21.34 |
| Indicator | IMXI | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 30.95 | 43.93 |
| Support Level | $14.87 | $12.98 |
| Resistance Level | $15.53 | $17.62 |
| Average True Range (ATR) | 0.21 | 0.54 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 36.32 | 37.07 |
International Money Express Inc is an omnichannel money remittance services company focused on the United States of America to Latin America and the Caribbean corridor, which includes Mexico, Central and South America and the Caribbean. The company offers wire transfer, money order, Foreign exchange, and cash checking services, while the majority of the revenue is derived from wire transfer and money order fees. The firm's business is organized around one reportable segment that provides money remittance services between the U.S. and Canada to Mexico, Guatemala, and other countries in Latin America, Africa, and Asia.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.